Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22853041 | 1.00 | P2RX7 (0.47) | P2RX7KDRBRAFSCN9AFFAR4 | |
| SCHEMBL22853085 | 0.91 | AKR1C2 (0.46) | P2RX7KDRBRAFSCN9AFFAR4 | |
| SCHEMBL30294438 | 0.91 | AKR1C2 (0.46) | P2RX7KDRBRAFSCN9AFFAR4 | |
| SCHEMBL22852997 | 0.84 | MAPK13 (0.47) | RAB9A | |
| SCHEMBL30294798 | 0.84 | MAPK13 (0.47) | RAB9A | |
| SCHEMBL22853059 | 0.82 | P2RX7 (0.44) | P2RX7KDRBRAFDHODH | |
| SCHEMBL30294481 | 0.82 | P2RX7 (0.44) | P2RX7KDRBRAFDHODH | |
| SCHEMBL22853358 | 0.81 | P2RX7 (0.44) | P2RX7KDRBRAFFFAR4RAB9A | |
| SCHEMBL30294670 | 0.81 | P2RX7 (0.44) | P2RX7KDRBRAFFFAR4RAB9A | |
| SCHEMBL22853208 | 0.81 | KDR (0.42) | P2RX7KDRBRAFRAB9AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | P2RX7 109/4885KDR 2754/4885BRAF 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.